CELC: the cash flow

MyFinsight

The latest financial statement is for the year ending 2025-12-31.

Cash Flow	2025-12-31
Net loss	-177,042
Depreciation	167
Stock-based compensation	21,383
Amortization of debt issuance costs and discount	3,137
Payment-in-kind interest	1,104
Non-cash operating lease expense	-7
Change in accrued interest income	-630
Prepaid clinical trial costs	12,127
Other current and non-current assets	2,991
Accounts payable	-3,040
Accrued clinical trial costs	118
Other accrued expenses	15,388
Net cash used in operating activities	-153,280
Proceeds from maturities of investments	332,507
Purchases of investments	396,342
Purchases of property and equipment	249
Net cash used in investing activities	-64,084
Proceeds from employee stock purchases	711
Proceeds from exercise of common stock options	3,485
Proceeds from exercise of common stock warrants	42,061
Proceeds from convertible debt, net of debt issuance costs of 6,246 and 0 during the years ended december 31, 2025 and 2024, respectively	195,004
Proceeds from note payable, net of debt issuance costs of 2,255 and 2,438 during the years ended december 31, 2025 and 2024, respectively	27,745
Proceeds from equity offering, net of underwriting discounts and offering costs	91,592
Payments for secondary registration statement costs	46
Net cash provided by financing activities	360,552
Net change in cash and cash equivalents	143,188
Beginning of period	22,515
End of period	165,703

Unit: Thousand (K) dollars (except for numbers of shares and EPS).